NEW POST
Latest News & Press From Rapha Capital Management & Our Portfolio Companies
NEW POST
3DBio Therapeutics, a biotech company in Queens, said it had for the first time used 3-D printing to make a…
FIZE Medical Ltd. FIZE an innovative provider of data derived from monitoring real-time urine output, announced today the closing of $4 million Series A-1 funding.
SPAC season is back as Arbor Rapha Capital Bioholdings, a blank-check company, lands on the public markets today to raise $150 million for a future biopharma merger. By Kyle LaHucik | Oct 29, 2021 10:15am | FierceBiotech
New deal with Takeda could mean up to $3.6 billion in milestone payments.
Demeetra Agbio, a Rapha portfolio company was recently featured in an article in the leading industry publication, CRISPR News MEDICINE. Demeetra AgBio, headquartered in Kentucky, is pioneering a unique genome-editing technology called Cas-CLOVER. Applications include plant-based drug development, enhanced bioprocessing for human and animal health, and engineering of crops and agricultural animals for improved traits. The author, Karen O’Hanlon Cohrt, spoke with Demeetra’s CEO Jack Crawford to hear more about Cas-CLOVER and its potential within human health and medicine.
MIAMI, June 25, 2020 /PRNewswire/ — Rapha Capital Management, LLC (https://raphacap.com), an investment management firm located in Miami, Florida, through Rapha Capital Investment XI,…
MIAMI, May 4, 2020 /PRNewswire/ — Rapha Capital Management, LLC (https://www.raphacap.com), an investment management firm located in Miami, Florida, through Rapha Capital Investment…
MIAMI, Oct. 2, 2019 /PRNewswire/ — Rapha Capital Management, LLC (https://www.raphacap.com), an investment management firm located in Miami, Florida, through Rapha Capital Investment…
MIAMI, April 22, 2019 /PRNewswire/ — Rapha Capital Management, LLC (https://www.raphacap.com), an investment management firm located in Miami, Florida, and their associated entities…